Jones K W, Hackett C J
ImmuLogic Pharmaceutical Corporation, Waltham, Massachusetts 02154, USA.
Cell Immunol. 1996 Nov 25;174(1):42-53. doi: 10.1006/cimm.1996.0292.
The upregulation of costimulatory molecules of antigen presenting cells (APC) resulting from interaction with activated T cells was studied in an in vitro system composed of well-characterized murine T hybridomas and B cell lymphomas. Increased B7-1 expression was induced on both MHC-matched and -mismatched (bystander) B lymphoma cells present in cultures of activated T hybridomas. Identical results were obtained with T hybridomas activated by either the appropriate peptide presented by MHC-matched APC or by mitogen stimulation in the absence of MHC/TCR cognate interactions. Soluble factors alone did not lead to upregulation of B7-1; B lymphomas cultured on the opposite side of a transwell membrane from an ongoing T cell stimulation response, or in supernatants of activated T cells, did not exhibit enhanced expression of B7-1. Antibodies to the CD40 ligand (CD40L) of T cells inhibited the increased appearance of B7-1 on B lymphomas. Significant B7-1 upregulation on the population of bystander B cells could be achieved even when they were present at a 10:1 excess over MHC-matched APC. These data indicate that B7-1 upregulation results from contact between bystander B cells and activated T hybridomas in vitro by CD40-CD40L interaction, without the requirement for TCR/MHC interaction.
在一个由特征明确的小鼠T杂交瘤和B细胞淋巴瘤组成的体外系统中,研究了抗原呈递细胞(APC)与活化T细胞相互作用导致的共刺激分子上调情况。在活化T杂交瘤培养物中存在的MHC匹配和不匹配(旁观者)B淋巴瘤细胞上均诱导了B7-1表达增加。用MHC匹配的APC呈递的适当肽或在没有MHC/TCR同源相互作用的情况下用丝裂原刺激激活的T杂交瘤也得到了相同的结果。单独的可溶性因子不会导致B7-1上调;在与正在进行的T细胞刺激反应隔着Transwell膜的另一侧培养的B淋巴瘤,或在活化T细胞的上清液中培养的B淋巴瘤,均未表现出B7-1表达增强。针对T细胞的CD40配体(CD40L)的抗体抑制了B淋巴瘤上B7-1增加的出现。即使旁观者B细胞比MHC匹配的APC多10倍,也能在其群体上实现显著的B7-1上调。这些数据表明,体外旁观者B细胞与活化T杂交瘤通过CD40-CD40L相互作用接触导致B7-1上调,而无需TCR/MHC相互作用。